Scholars Central

Conference abstract

Treatment of extrapyramidal symptoms in patients treated with antipsychotic drugs

Authors: Felix-Martin Werner, Covenas Rafael

Euro Academy Poßneck, Germany Institute of Neuroscience of Castilla y Leon, Spain

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Extrapyramidal symptoms, for example dyskinesia, parkinsonism, akathisia or dystonia can occur in schizophrenic or schizoaffective patients treated with antipsychotic drugs. Second-generations antipsychotic drugs such as risperidone, olanzapine, quetiapine mostly are D2 and 5-HT2A antagonists and can cause these movement disturbances as a consequence of the D2 receptor blockade. In the mesolimbic system, the prefrontal cortex and the hippocampus, dopamine and serotonin hyperactivity and GABA and glutamate hypoactivity are induced by susceptibility genes found in schizophrenia and schizoaffective disorder. The function of neurotransmitters and neuropeptides in the extrapyramidal system are reviewed. Neural networks in the extrapyramidal system and the mesolimbic system are described. In the extrapyramidal system, the neurotransmitter balance between D2 dopaminergic and muscarinic cholinergic neurons and between presynaptic GABAergic and excitotoxic glutamatergic neurons is altered by the second-generation antipsychotic drugs. Possible treatments of extrapyramidal symptoms induced by antipsychotic drugs are M4 antagonists, GABAA agonists and NMDA antagonists. The adverse effects of these additional drugs are presented. Some new antipsychotic drugs such as aripiprazole and cariprazine less often and to a lesser extent cause extrapyramidal symptoms, because they have a partial agonism at the D2 receptor. Recent Publications 1. Werner F M and Covenas R (2017) Extrapyramidal symptoms in patients treated with antipsychotic drugs. J Bioequiv Abailab. 9:3. 2. Werner F M and Covenas R (2016) Pharmacological options in the treatment of antipsychotic-induced extrapyramidal symptoms. J Cytol Histol. 7:2. 3. Werner F M and Covenas R (2015) Classical neurotransmitters and neuropeptides involved in Parkinson’s disease: focus on anti-Parkinsonian drugs. Curr Drug Ther. 10(2)66-81. 4. Werner F M and Covenas R (2015) New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag. 11:1657-1661. 5. Werner F M and Covenas R (2014) Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Exp Opin Drug Saf. 13:1031-1042

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutics & Drug Delivery Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutics & Drug Delivery Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Felix-Martin Werner”
  • BylineArticles whose byline prints “Covenas Rafael”